Operating profit before amortization: vaxcyte.com (PCVX)

Brandmark of Vaxcyte Inc (PCVX)

The growth dynamics of the biochemist workforce and the success of clinical trials define the trend, which the EBITDA of Vaxcyte, Inc. (PCVX) on GURU.Markets reflects in detail, where 0.00 shows the level of this metric. Market capitalization is based on the commercialization of high-margin pneumococcal vaccines. Scaling potential allows the drug to be produced in millions of units with minimal manufacturing costs.

PCVX: Vaxcyte Operating profit EBITDA 11/23/2025 - 11/10/2026

Vaxcyte - analytical breakdowns and key metrics (PCVX)

- stock value and consensus price forecast:
Market Chart SutroVax|PCVX - Price Target Chart
- company stock exchange capitalization indicators:
Market Capitalization Vaxcyte|PCVX - Enterprise Value
- balance sheet net asset value indicators:
Share Book Value Vaxcyte|PCVX - Book Capitalization|Market-to-Book Ratio vaxcyte.com|PCVX - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Equity Ratio Vaxcyte, Inc.|PCVX - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Vaxcyte Inc|PCVX - Company Aggregate Debts|Debts to Net Assets Vaxcyte|PCVX - Company Long-Term Debt|Short-Term Debt Vaxcyte|Immediate Liquidity Ratio vaxcyte.com
- earnings and valuation multiples information:
PCVX - Company Net Income|Company Profit Forecast Vaxcyte, Inc.|PCVX - Price to Earnings Ratio|Future Price to Earnings vaxcyte.com|PCVX - PEG Multiple|EV/EBITDA Multiple Vaxcyte|PCVX - Operating profit before deduction of amortization|Earnings per share for the last 12 months Vaxcyte|PCVX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months vaxcyte.com|PCVX - Net earnings per share growth this year|Expected net earnings per share growth next year Vaxcyte, Inc.
Summary company analytics:PCVX SutroVax
Mass-produced product of vaxcyte.com

Vaxcyte, Inc. (PCVX) absolute operating profit reflects the cash flow from core operations before interest and taxes, demonstrating cost management efficiency amid extensive outsourcing of development and production. By analyzing changes in EBITDA_Co, an investor assesses the actual volume of generated funds relative to historical data, which allows for the determination of the business model's sustainability and the risk of overpaying for the asset's future potential.

Competitors of Vaxcyte, Inc. (PCVX)

Operating income before deduction of amortization Summit Pharma (SMMT)|MRNA - Profit before payment of interest, taxes and amortization|TARS (tarsusrx.com) - Operating profit before amortization|CRMD: Operating profit EBITDA|Profit before deduction of interest, taxes, depreciation and amortization MCRB (Seres Therapeutics Inc.)|SPRO (Spero) - Operating profit EBITDA|Profit before interest, taxes and amortization Scynexis SCYX|Operating profit EBITDA ANTX|Operating profit before deduction of amortization polypid.com PYPD|LakeShore Biopharma - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization ITRM (Iterum Therapeutics PLC)|BiomX Ltd - Operating profit EBITDA|Operating income before deduction of amortization Soligenix, Inc. SNGX|60degreespharma.com (SXTP) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization oragenics.com (OGEN)|Profit before payment of interest, taxes and amortization OpGen